You are currently browsing the archives for 16 December 2015.
Displaying 1 entry.

This press release contains forward-looking statements.

The company assumes no obligation to update forward-looking statements new information, events new information, events or circumstances after the date reflect reflect the occurrence of unanticipated events.. This press release contains forward-looking statements, including statements regarding the Company’s business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company’s actual results could differ materially from those that are associated with these forward-looking statements on a number of factors, including risks and uncertainties associated with the Company’s research and development activities specified the results of pre – clinical development of the receipt and timing of regulatory approvals, market acceptance of the Company’s products on offer, the company anticipated operating losses, need for future capital and ability obtain future funding, competition from third parties, and the ability to get the company and protect intellectual property rights, the Company’s dependence on third-party manufacturers and suppliers, the company’s lack of sales and marketing experience, the Company’s ability to attract and retain, changes in technology, government regulation and general market conditions and the risks and uncertainties described in the Company’s current and periodic filings with the Securities and Exchange Commission , including the company’s Annual Report on Form 10 – K for the year ended 31 December 2007 and its Quarterly Report on Form 10-Q for the quarter ended 31 March 2008.

– Phase 1 Combination Study with pegylated liposomal doxorubicin : Abstract# 2568final results from a Phase 1 trial of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignanciesDizon DS, Maluf F, Aghajanian CA, Sabbatini P, Soignet S, S and Spriggs DR PezzulliGeneral Poster Session: Sunday, 00 to 18.00 clock CDT S Hall A1, Poster# 12HPoniard Investor eventin addition to the picoplatin poster presentations will be Poniard host an investor meeting on Sunday, at 6:30 clock in Chicago. Prostate cancer expert E. David Crawford, from the University of Colorado Health Sciences Center in Denver;; The event will include presentations and discussions with expert oncologists, including lung cancer expert Chandra Belani, of the University of Pittsburgh Medical Center and platinum therapy developer, Lloyd Kelland, of Cancer Research Technology and University College London, as well as members of the Executive Poniard..